Geron Corp

Research Geron Corp (GERN) on Bullrun: market cap USD 833.98M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGERN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 833.98M
• Financial periodFY2025
• Net income-USD 83.50M

Valuation Snapshot

latest market cap is USD 833.98M.

About Geron Corp

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis;

Frequently asked questions

What is Geron Corp's market cap?

Geron Corp's market capitalization is USD 833.98M.

What does Geron Corp do?

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.